A RETROSPECTIVE PREMIER DATABASE STUDY TO EVALUATE DIFFERENCES BETWEEN PROGEL™ PLEURAL AIR LEAK SEALANT AS COMPARED WITH OTHER SEALANTS IN THE INPATIENT SURGICAL SETTING
Author(s)
Mortman K1, Corral M2, Zhang X2, Berhane I2, Bourque M3, Ferko N3
1George Washington University Hospital, Washington, DC, USA, 2C.R. Bard Inc., Murray Hill, NJ, USA, 3Cornerstone Research Group Inc., Burlington, ON, Canada
OBJECTIVES: Air leaks after thoracic surgery are common, and can be associated with an increased risk of clinical complications and a significant economic burden, including increased length of stay and hospital resources. PROGEL™ Pleural Air Leak Sealant (PROGEL™) is the only FDA-approved sealant to treat intra-operative air leaks. The analyses presented here estimate healthcare utilization, medical costs, and outcomes in patients treated with PROGEL™ as compared to those outcomes associated with the use of other synthetic sealants or fibrin sealants. METHODS: This was a retrospective analysis of both open and thoracoscopic lung resections including: lobectomy, bilobectomy, segmentectomy, decortication procedures, and wedge resections from the Premier Hospital Database, evaluating the clinical and economic outcomes of patients whose discharge data included ICD-9 codes for these procedures in the inpatient setting. Patients were analyzed using propensity score matching (PSM) to compare the use of PROGEL™ with other sealants (synthetic and fibrin). Adult patients (18 and older) with a hospitalization discharge between January 2009 and June 2015 were evaluated. Total costs, length of stay, readmissions, and clinical complications were collected. RESULTS: PSM produced cohorts of 3,988 for PROGEL™, and 3,639 for other sealants. Utilization of PROGEL™ was associated with an adjusted all-cause mean cost savings of $4,062 as compared with other synthetic and fibrin sealants; $31,795 versus $35,858, p<0.001. PROGEL™ was also associated with an adjusted mean length of stay reduction of 1.35 days as compared with other synthetic and fibrin sealants (9.8 versus 11.2 days, p<0.001), and reduced risk of moderate or low infection. CONCLUSIONS: After controlling for patient characteristics, risk factors, and comorbidities, as well as hospital characteristics and surgical procedures, a statistically significant lower healthcare utilization and hospital cost was found to be associated with the use of PROGEL™ compared to the use of other synthetic or fibrin sealants.
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PMD39
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies, Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Respiratory-Related Disorders